within Pharmacolibrary.Drugs.ATC.L;

model L04AA40
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.37,
    Cl             = 0.00037,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.48,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 15.0,            
    Vdp             = 0.19,
    k12             = 34.4,
    k21             = 34.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AA40</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cladribine is a purine nucleoside analog used as an antineoplastic and immunosuppressive agent. It is primarily indicated for the treatment of hairy cell leukemia and, more recently, approved for relapsing forms of multiple sclerosis in adults. Cladribine is approved and used in various countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with multiple sclerosis after oral administration of cladribine tablets.</p><h4>References</h4><ol><li><p>Hermann, R, et al., &amp; Dong, JQ (2025). Effect of Cladribine Tablets on the Pharmacokinetics of a Combined Oral Contraceptive in Pre-Menopausal Women With Relapsing Multiple Sclerosis. <i>Clinical and translational science</i> 18(4) e70204–None. DOI:<a href=\"https://doi.org/10.1111/cts.70204\">10.1111/cts.70204</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40170281/\">https://pubmed.ncbi.nlm.nih.gov/40170281</a></p></li><li><p>Liliemark, J (1997). The clinical pharmacokinetics of cladribine. <i>Clinical pharmacokinetics</i> 32(2) 120–131. DOI:<a href=\"https://doi.org/10.2165/00003088-199732020-00003\">10.2165/00003088-199732020-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9068927/\">https://pubmed.ncbi.nlm.nih.gov/9068927</a></p></li><li><p>Savic, RM, et al., &amp; Karlsson, MO (2017). Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. <i>Clinical pharmacokinetics</i> 56(10) 1245–1253. DOI:<a href=\"https://doi.org/10.1007/s40262-017-0516-6\">10.1007/s40262-017-0516-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28255849/\">https://pubmed.ncbi.nlm.nih.gov/28255849</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AA40;
